House panel supports 12-year exclusivity for biotech drugs

08/3/2009 | Wall Street Journal, The

The House Energy and Commerce Committee voted 47-11 to approve a measure that would give 12 years of market protection to brand-name biotech medicines. The amendment "takes a balanced approach between innovation, cost savings for consumers and safety," said a spokeswoman for Rep. Jay Inslee, D-Wash., one of the sponsors of the bill.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park